Development and Validation of a Noninvasive Model for the Detection of High-Risk Varices in Patients with Unresectable HCC.

HCC NPV non-invasive portal hypertension

Journal

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
ISSN: 1542-7714
Titre abrégé: Clin Gastroenterol Hepatol
Pays: United States
ID NLM: 101160775

Informations de publication

Date de publication:
30 Jul 2024
Historique:
received: 08 04 2024
revised: 02 07 2024
accepted: 03 07 2024
medline: 2 8 2024
pubmed: 2 8 2024
entrez: 1 8 2024
Statut: aheadofprint

Résumé

Non-invasive variceal risk stratification systems have not been validated in patients with hepatocellular carcinoma (HCC), which presents logistical barriers for patients in the setting of systemic HCC therapy. We aimed to develop and validate a non-invasive algorithm for the prediction of varices in patients with unresectable HCC. We performed a retrospective cohort study in 21 centers in the US including adult patients with unresectable HCC and Child Pugh A5-B7 cirrhosis diagnosed between 2007 and2019. We included patients who completed an esophagogastroduodonoscopy (EGD) within 12 months of index imaging but prior to HCC treatment. We divided the cohort into a 70:30 training set and validation set, with the goal of maximizing negative predictive value (NPV) to avoid EGD in low-risk patients. We included 707 patients (median age 64.6 years, 80.6% male and 74.0% White). Median time from HCC diagnosis to EGD was 47 (IQR: 114) days, with 25.0% of patients having high-risk varices. A model using clinical variables alone achieved a NPV of 86.3% in the validation cohort, while a model integrating clinical and imaging variables had an NPV 97.4% in validation. The clinical and imaging model would avoid EGDs in over half of low-risk patients while misclassifying 7.7% of high-risk patients. A model incorporating clinical and imaging data can accurately predict the absence of high-risk varices in patients with HCC and avoid EGD in many low-risk patients prior to the initiation of systemic therapy, thus expediting their care and avoiding treatment delays.

Sections du résumé

BACKGROUND AND AIMS OBJECTIVE
Non-invasive variceal risk stratification systems have not been validated in patients with hepatocellular carcinoma (HCC), which presents logistical barriers for patients in the setting of systemic HCC therapy. We aimed to develop and validate a non-invasive algorithm for the prediction of varices in patients with unresectable HCC.
METHODS METHODS
We performed a retrospective cohort study in 21 centers in the US including adult patients with unresectable HCC and Child Pugh A5-B7 cirrhosis diagnosed between 2007 and2019. We included patients who completed an esophagogastroduodonoscopy (EGD) within 12 months of index imaging but prior to HCC treatment. We divided the cohort into a 70:30 training set and validation set, with the goal of maximizing negative predictive value (NPV) to avoid EGD in low-risk patients.
RESULTS RESULTS
We included 707 patients (median age 64.6 years, 80.6% male and 74.0% White). Median time from HCC diagnosis to EGD was 47 (IQR: 114) days, with 25.0% of patients having high-risk varices. A model using clinical variables alone achieved a NPV of 86.3% in the validation cohort, while a model integrating clinical and imaging variables had an NPV 97.4% in validation. The clinical and imaging model would avoid EGDs in over half of low-risk patients while misclassifying 7.7% of high-risk patients.
CONCLUSION CONCLUSIONS
A model incorporating clinical and imaging data can accurately predict the absence of high-risk varices in patients with HCC and avoid EGD in many low-risk patients prior to the initiation of systemic therapy, thus expediting their care and avoiding treatment delays.

Identifiants

pubmed: 39089513
pii: S1542-3565(24)00678-5
doi: 10.1016/j.cgh.2024.07.008
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Auteurs

Neehar D Parikh (ND)

University of Michigan, Ann Arbor, MI. Electronic address: ndparikh@med.umich.edu.

Patricia Jones (P)

University of Miami, Miami, FL.

Reena Salgia (R)

Henry Ford Health, Detroit, MI.

Irun Bhan (I)

Massachusetts General Hospital, Boston, MA.

Lauren T Grinspan (LT)

The Mount Sinai Hospital, New York, NY.

Janice H Jou (JH)

Oregon Health Science University, Portland, OR.

Kali Zhou (K)

University of Southern California, Los Angeles, CA.

Prasun Jalal (P)

Baylor College of Medicine, Houston, TX.

Giorgio Roccaro (G)

Emory University, Atlanta, GA.

Amol S Rangnekar (AS)

Georgetown University, District of Columbia.

Jihane N Benhammou (JN)

University of California Los Angeles, Los Angeles, CA.

Anjana Pillai (A)

University of Chicago, Chicago, IL.

Neil Mehta (N)

University of San Francisco, San Francisco, CA.

Joel Wedd (J)

Virginia Commonwealth University, Richmond, VA.

Ju Dong Yang (JD)

Cedars-Sinai Medical Center, Los Angeles, CA.

Amy K Kim (AK)

Johns Hopkins University, Baltimore, MD.

Andres Duarte-Rojo (A)

Northwestern University, Chicago, IL.

Omobonike O Oloruntoba (OO)

Duke University, Durham, NC.

Amit Tevar (A)

University of Pittsburgh, Pittsburgh, PA.

Jennifer S Au (JS)

Scripps Health, San Diego, CA.

Yamile Blain (Y)

University of Miami, Miami, FL.

Sanjana Rao (S)

University of Miami, Miami, FL.

Onofrio A Catalano (OA)

Massachusetts General Hospital, Boston, MA.

Sara Lewis (S)

The Mount Sinai Hospital, New York, NY.

Mishal Mendiratta-Lala (M)

University of Michigan, Ann Arbor, MI.

Kevin King (K)

University of Southern California, Los Angeles, CA.

Lekha Sachdev (L)

Georgetown University, District of Columbia.

Edward W Lee (EW)

University of California Los Angeles, Los Angeles, CA.

Jill Bruno (J)

Virginia Commonwealth University, Richmond, VA.

Ihab Kamel (I)

Johns Hopkins University, Baltimore, MD.

Celestina Tolosa (C)

Johns Hopkins University, Baltimore, MD.

Karissa Kao (K)

University of Michigan, Ann Arbor, MI.

Tarek Badawi (T)

Henry Ford Health, Detroit, MI.

Eric M Przybyszewski (EM)

Massachusetts General Hospital, Boston, MA.

Lisa Quirk (L)

University of Texas Southwestern, Dallas, TX.

Piyush Nathani (P)

University of Texas Southwestern, Dallas, TX.

Brandy Haydel (B)

The Mount Sinai Hospital, New York, NY.

Emily Leven (E)

The Mount Sinai Hospital, New York, NY.

Nicole Wong (N)

Oregon Health Science University, Portland, OR.

Robert Albertian (R)

University of Southern California, Los Angeles, CA.

Ariana Chen (A)

University of Southern California, Los Angeles, CA.

Fuad Z Aloor (FZ)

Baylor College of Medicine, Houston, TX.

Islam B Mohamed (IB)

Baylor College of Medicine, Houston, TX.

Ahmed Elkheshen (A)

Baylor College of Medicine, Houston, TX.

Charles Marvil (C)

Emory University, Atlanta, GA.

Gerard Issac (G)

Emory University, Atlanta, GA.

Joseph W Clinton (JW)

Georgetown University, District of Columbia.

Stephanie M Woo (SM)

Georgetown University, District of Columbia.

Jung Yum (J)

University of California Los Angeles, Los Angeles, CA.

Erin Rieger (E)

University of Chicago, Chicago, IL.

Alan L Hutchison (AL)

University of Chicago, Chicago, IL.

Don A Turner (DA)

Virginia Commonwealth University, Richmond, VA.

Manaf Alsudaney (M)

Cedars-Sinai Medical Center, Los Angeles, CA.

Perla Hernandez (P)

Cedars-Sinai Medical Center, Los Angeles, CA.

Ziyi Xu (Z)

Johns Hopkins University, Baltimore, MD.

Abdullah Khalid (A)

Scripps Health, San Diego, CA.

Bethany Barrick (B)

Scripps Health, San Diego, CA.

Bo Wang (B)

University of Michigan, Ann Arbor, MI.

Elliot B Tapper (EB)

University of Michigan, Ann Arbor, MI.

Wei Hao (W)

University of Michigan, Ann Arbor, MI.

Amit G Singal (AG)

University of Texas Southwestern, Dallas, TX.

Classifications MeSH